A Feasibility Trial to Evaluate Endoscopic Removal of early esophageal neoplasia using Endoscopic Submucosal Dissection with LumenR Esophageal RetractorTM (LER), a Modified Esophageal Overtube - LumenR feasibility trial

Academisch Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Age from 18 to 90 years.
•2. An early esophageal neoplastic lesion with a biopsy-based histological diagnosis of either early Barrett*s neoplasia (i.e. high-grade dysplasia or early adenocarcinoma) or early esophageal squamous neoplasia (i.e. high-grade dysplasia or early squamous carcinoma).
•3. The lesion of interest should appear endoscopically resectable according to the discretion of two experienced interventional endoscopists with specific interest in the field of early upper GI neoplasia treatment.
•4. The lesion of interest should have a maximum longitudinal extent of 80-mm.
•5. The lesion of interest should have a maximum circumferential extent of less than 75%.
•6. Patients with early Barrett*s neoplasia should have at least one of the following endoscopic features, which may compromise the radicality of the deeper resection margin and/or the histological assessment of the cancer when using cap-based endoscopic piecemeal resection: a) a bulky intraluminal component; b) lesions with an area suspicious for invasive cancer >20-mm; or c) lesions suspicious for submucosal invasion.
•7. Subject is able to understand the risks and benefits of participating in the study and must be willing to sign and date the Informed Consent Form for this study approved by the Institutional Review Board (IRB.)

•1. Clear presence of invasion into the proper muscle layer of the esophagus on endoscopic ultrasound.
•2. Local lymph node metastasis on EUS with positive fine needle aspiration.
•3. Patients with esophageal narrowing restricting passage of a 20-mm Savary bougie prior to the procedure.
•4. Patients with uncorrectable bleeding disorders (INR more than 1.5, platelet count less than 50,000).
•5. Patients with esophageal varices
•6. Subjects has allergy to materials from which the device is constructed: PVC, Nitinol, Watershed, Polycarbonate, and PTFE.
•7. Subjects who received any experimental drug or device within the previous three months.
•8. Patients who are not able to sign informed consent, or do not understand the content of the IC

发起方